• Nenhum resultado encontrado

Rev. Bras. Hematol. Hemoter. vol.38 número2

N/A
N/A
Protected

Academic year: 2018

Share "Rev. Bras. Hematol. Hemoter. vol.38 número2"

Copied!
2
0
0

Texto

Loading

Referências

Documentos relacionados

Clinical evidence of a GvL effect after allo HSCT is suggested by a plateau in relapse risk that is reached 2–5 years following allo HSCT, indicating that a substantial pro- portion

When sub-scales were compared, oral symptoms and functional limitations had a greater negative impact on the quality of life of adolescents with sickle cell disease ( p -value

Method: Bone marrow samples from patients with multiple myeloma were used to stan- dardize a panel of five probes [1q amplification, 13q14 deletion, 17p deletion, t(4;14), and

CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; BCL-U: B-cell lymphoma, unclassifiable, with features intermediate between

As there is no curative therapy, researchers have been investigating new drugs to treat myeloproliferative neoplasms, including l -amino acid oxidase from Calloselasma rhodostoma

Moreover, the addition of betaine or sodium-4-phenylbutyrate increased the secretion rate of FVIII B proteins in HEK 293 cells, but the same effect was not seen for FVIII

This study describes the prevalence of anemia, hypertension and diabetes and the overall health status in pre-elderly and elderly subjects enrolled in two primary health care

Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts